Updated:
Upcoming Laboratorios Farmacéuticos Rovi dividendThere are no announced dividends from Laboratorios Farmacéuticos Rovi for 2026.
Laboratorios Farmacéuticos Rovi (ROVI) credited 0.9594 euros in dividends on July 15, 2026.
Laboratorios Rovi does not have a defined dividend policy, so it is difficult to predict the amount to be distributed by dividend. However, with the exception of the year affected by the covid 19 pandemic, it has always paid its shareholders the first week of July.
By 2023, they expect a decline in consolidated net income due to the uncertainty that pharma will face in the wake of the pandemic.
So, despite the stock market and profit increase in 2021, it is not easy to foresee what Rovi will do with its dividends in 2023, 2024 or 2025.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio Laboratorios Farmacéuticos Rovi Dividends
- Payout Ratio27.01%
- Retained Earnings72.99%
An appropriate payout ratio may vary depending on the industry, the company's growth stage and its financial health.
Dividend calendar of Laboratorios Farmacéuticos Rovi
There is no Dividend Calendar of Laboratorios Farmacéuticos Rovi defined for 2026.
For a company to have growing dividends by our standards, the annual dividend amount must have increased steadily for at least the last 5 years.
The company's dividend yield is compared to the industry average to determine its positioning.
Imagine you have a list of dividend yields for different companies in an industry. If you look for the "top 25% percentile", you will find a number. This number tells you that the top 25% of the companies with the highest dividends have a yield higher than that number. On the other hand, the "top 75% percentile" shows you another number, which tells you that 75% of the companies have a higher yield than that number, thus showing a more common and less high yield.
For a company to have stable dividends by our standards, it is vital that it has not had an annual decline of more than 10% over the previous year.
Dividend history of Laboratorios Farmacéuticos Rovi
In this table you can see the complete history:
| Year | Ex-Dividend | Amount | Total |
|---|---|---|---|
| 2026 |
07/13/2026 |
0.9594 € |
0.9594 € |
| 2025 |
07/14/2025 |
0.9351 € |
0.9351 € |
| 2024 |
07/08/2024 |
1.1037 € |
1.1037 € |
| 2023 |
07/03/2023 |
1.2938 € |
1.2938 € |
| 2022 |
07/05/2022 |
0.9556 € |
0.9556 € |
| 2021 |
07/05/2021 |
0.3812 € |
0.3812 € |
| 2020 |
11/17/2020 |
0.1751 € |
0.1751 € |
| 2019 |
07/02/2019 |
0.0798 € |
0.0798 € |
| 2018 |
07/03/2018 |
0.1207 € |
0.1207 € |
| 2017 |
07/03/2017 |
0.183 € |
0.183 € |
| 2016 |
06/30/2016 |
0.139 € |
0.139 € |
| 2015 |
07/02/2015 |
0.169 € |
0.169 € |
| 2014 |
07/03/2014 |
0.1612 € |
0.1612 € |
| 2013 |
07/03/2013 |
0.1366 € |
0.1366 € |
| 2012 |
07/04/2012 |
0.1269 € |
0.1269 € |
| 2011 |
07/06/2011 |
0.17208 € |
0.1721 € |
| 2010 |
07/06/2010 |
0.141 € |
0.141 € |
| 2009 |
07/08/2009 |
0.0865 € |
0.0865 € |
| 2008 |
09/17/2008 |
0.0783 € |
0.0783 € |
Information about Laboratorios Farmacéuticos Rovi
Laboratorios Farmacéuticos Rovi is a Spanish pharmaceutical company based in Madrid specialized in the research, development, manufacture and commercialization of generic drugs and pharmaceutical specialties.
Rovi focuses a large part of its efforts on the research and development of new drugs, having one of the largest R&D laboratories in Europe.
Rovi has achieved great milestones throughout its history, such as the patent of heparin or the agreement with the American pharmaceutical giant Pzifer to bring terramycin (an antibiotic with countless uses) to Spain in 1952. In recent years, specifically in July 2020, it was chosen by Moderna to manufacture the COVID-19 vaccine in Madrid as soon as it became available.
Frequently asked questions about Laboratorios Farmacéuticos Rovi dividends
Laboratorios Farmacéuticos Rovi pays dividends on a Annual basis.
Laboratorios Farmacéuticos Rovi is listed on the Madrid Stock Exchange and is part of the Ibex 35.
Laboratorios Farmacéuticos Rovi has the Ticker or stock code BME:ROVI.
The CEO of Laboratorios Farmacéuticos Rovi in 2026 is Mr. Juan Lopez-Belmonte Encina.
The ISIN of Laboratorios Farmacéuticos Rovi is ES0157261019.
Laboratorios Farmacéuticos Rovi does not have a growing dividend program. Dividends have not shown a steady growth in the last 5 years.
Check the latest comments and participate in the live chat on Laboratorios Farmacéuticos Rovi stocks (ROVI).
No comments yet. Be the first to join in.